Literature DB >> 11496957

Receptor-mediated targeting of spray-dried lipid particles coformulated with immunoglobulin and loaded with a prototype vaccine.

A I Bot1, D J Smith, S Bot, L Dellamary, T E Tarara, S Harders, W Phillips, J G Weers, C M Woods.   

Abstract

PURPOSE: Spray-dried lipid-based microparticles (SDLM) serve as a platform for delivery of a wide variety of compounds including peptides, proteins, and vaccines to the respiratory mucosa. In the present study, we assessed the impact of IgG-mediated targeting to phagocytic cells of inactivated influenza virus formulated in SDLM, on subsequent immune responses.
METHODS: SDLM were produced containing inactivated influenza virus strain A/WSN/32/H1N1 (WSN), with or without IgG. Using phagocytic antigen presenting cells (APC) and a T cell hybridoma (TcH) line specific for a dominant influenza virus epitope, we compared the in vitro responses elicited by ligand-formulated (SDLM-IgG-WSN) and non-ligand particles (SDLM-WSN). The effect of including the IgG ligand in the formulation was further characterized by measuring the immune responses of rodents vaccinated with SDLM.
RESULTS: SDLM-IgG-WSN were internalized in an Fc receptor (FcR)-dependent manner by phagocytic APC that were then able to effectively present a dominant, class II-restricted epitope to specific T cells. While SDLM-WSN elicited a lower response than administration of plain inactivated virus in saline, the level of the T cell response was restored both in vitro and in vivo by incorporating the APC FcR ligand, IgG, in the SDLM.
CONCLUSIONS: Incorporation of FcR ligand (IgG) in SDLM restored the limited ability of formulated virus to elicit T-cell immunity, by receptor-mediated targeting to phagocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11496957     DOI: 10.1023/a:1010988311640

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  28 in total

Review 1.  Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination.

Authors:  P Johansen; Y Men; H P Merkle; B Gander
Journal:  Eur J Pharm Biopharm       Date:  2000-07       Impact factor: 5.571

2.  Liposomes as immunological adjuvants.

Authors:  A C Allison; G Gregoriadis
Journal:  Recent Results Cancer Res       Date:  1976

3.  Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract.

Authors:  A I Bot; T E Tarara; D J Smith; S R Bot; C M Woods; J G Weers
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

4.  Immune lysis of liposomes and erythrocyte ghosts loaded with spin label.

Authors:  G K Humphries; H M McConnell
Journal:  Proc Natl Acad Sci U S A       Date:  1974-05       Impact factor: 11.205

5.  Isolation of apoproteins from canine surface active material.

Authors:  R J King; D J Klass; E G Gikas; J A Clements
Journal:  Am J Physiol       Date:  1973-04

Review 6.  Factors and events in the activation, proliferation, and differentiation of B cells.

Authors:  W O Weigle
Journal:  Crit Rev Immunol       Date:  1987       Impact factor: 2.214

7.  Migration of alveolar macrophages from alveolar space to paracortical T cell area of the draining lymph node.

Authors:  T Thepen; E Claassen; K Hoeben; J Brevé; G Kraal
Journal:  Adv Exp Med Biol       Date:  1993       Impact factor: 2.622

8.  Studies of the 1996-1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness.

Authors:  E S Hurwitz; M Haber; A Chang; T Shope; S T Teo; J S Giesick; M M Ginsberg; N J Cox
Journal:  J Infect Dis       Date:  2000-09-08       Impact factor: 5.226

9.  Spleen-derived stromal cells. Adhesion molecules expression and lymphocyte adhesion to reticular cells.

Authors:  A Castro; M R Bono; V Simon; L Vargas; M Rosemblatt
Journal:  Eur J Cell Biol       Date:  1997-12       Impact factor: 4.492

10.  Migration of dendritic cells into the draining lymph nodes of the lung after intratracheal instillation.

Authors:  C E Havenith; P P van Miert; A J Breedijk; R H Beelen; E C Hoefsmit
Journal:  Am J Respir Cell Mol Biol       Date:  1993-11       Impact factor: 6.914

View more
  6 in total

Review 1.  Targeting vaccines to dendritic cells.

Authors:  Camilla Foged; Anne Sundblad; Lars Hovgaard
Journal:  Pharm Res       Date:  2002-03       Impact factor: 4.200

Review 2.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

Review 3.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

4.  Preparation and characterization of nickel nanoparticles for binding to his-tag proteins and antigens.

Authors:  Jigna D Patel; Ronan O'Carra; Julia Jones; Jerold G Woodward; Russell J Mumper
Journal:  Pharm Res       Date:  2006-12-19       Impact factor: 4.200

Review 5.  Development of stable influenza vaccine powder formulations: challenges and possibilities.

Authors:  J-P Amorij; A Huckriede; J Wilschut; H W Frijlink; W L J Hinrichs
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

6.  The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response.

Authors:  Antoine Minne; Jamila Louahed; Sybille Mehauden; Benoît Baras; Jean-Christophe Renauld; Rita Vanbever
Journal:  Immunology       Date:  2007-05-22       Impact factor: 7.397

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.